News & Media

Take a closer look at what we’re doing across Teva worldwide

Our latest news

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conf...

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferenc

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississipp...

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, an

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risper...

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class P...

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potent

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-...

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A)

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Prop...

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarte...

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Pro...

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept...

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in
See all news items
Previous
Next

Discover the world of Teva

Follow our latest feature stories with news and views from across our global organization

Discover more Discover the world of Teva

Media Resources

Media Inquiries

Contact our corporate communications.

Learn more Media Inquiries

Media Kit

Files and resources for media use only

Download Teva Media Kit Media Kit

Financial Reports

View Teva financial news on our global website.

Learn more Financial Reports

Connect with us

Teva Social Media Guidelines.

Learn more Connect with us